Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
National Institutes of Health
- Posted
- Dec 17, 2025
- Amount
- $3,000,000
- Listing close date, not an application deadline
- Aug 21, 2028
Similar opportunities open now
- National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Dec 2027
- Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses May 2027
- Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Dec 2027
- High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Mar 2027Up to $1.5M
Classification and identifiers
- Solicitation number
- PAR-25-446
- Assistance listing (CFDA)
- 93.279
Amount
$3,000,000
Who can apply
Public colleges and universities, State government agencies, and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.
About this opportunity
The purpose of this Funding Opportunity (NOFO) is to solicit grant applications to support research on the discovery and development of interventions to prevent and/or treat substance use disorders (SUDs) and overdose, including medications and medical devices to treat co-morbid SUDs. This includes preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate interventions closer to regulatory approval or clinical adoption. This NOFO will utilize the UG3/UH3 activity code.